{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:27:27Z","timestamp":1787498847186,"version":"build-2736575974"},"posted":{"date-parts":[[2024,5,29]]},"group-title":"In Review","reference-count":36,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T00:00:00Z","timestamp":1716940800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,12,14]]},"abstract":"<title>Abstract<\/title>\n                <p>Background\n With the approval of disease-modifying treatments (DMTs) for early Alzheimer\u2019s disease (AD), there is an increased need for efficient and non-invasive detection methods for cerebral amyloid-\u03b2 (A\u03b2) pathology. Current methods, including positron emission tomography (PET) and cerebrospinal fluid (CSF) analysis, are costly and invasive methods that may limit access to new treatments. Plasma tau phosphorylated at threonine-217 (P-tau217) presents a promising alternative, yet optimal cutoffs for treatment eligibility with DMTs like aducanumab require further investigation. This study evaluates the efficacy of one- and two-cutoff strategies for determining DMT eligibility at the Butler Hospital Memory &amp; Aging Program (MAP).\nMethods\n In this retrospective, cross-sectional diagnostic cohort study, we first developed P-tau217 cutoffs using site-specific training data and BioFINDER-2, which were then tested in potential DMT candidates from Butler MAP (total n\u2009=\u2009150). ROC analysis was used to calculate the area under the curve (AUC) and accuracy of P-tau217 interpretation strategies, using A\u03b2-PET\/CSF testing as the standard of truth.\nResults\n Potential DMT candidates at Butler MAP (n\u2009=\u200950), primarily diagnosed with mild cognitive impairment (n\u2009=\u200929 [58%]) or mild dementia (21 [42%]), were predominantly A\u03b2-positive (38 [76%]), and half (25 [50%]) were subsequently treated with aducanumab. Elevated P-tau217 predicted cerebral A\u03b2 positivity in potential DMT candidates (AUC\u2009=\u20090.97 [0.92-1]), with diagnostic accuracy ranging from 0.88 (0.76\u20130.95, p\u2009=\u20090.028) to 0.96 (0.86-1, p\u2009&lt;\u2009.001). When using site-specific cutoffs, a subset of DMT candidates (10%) exhibited borderline P-tau217 (between 0.273 and 0.399 pg\/mL) that would have potentially required from confirmatory testing.\nConclusions\n This study, which included participants treated with aducanumab, confirms the utility of one- and two-cutoff strategies for interpreting plasma P-tau217 in assessing DMT eligibility. Using P-tau217 could potentially replace more invasive diagnostic methods, and all aducanumab-treated participants would have been deemed eligible based on P-tau217. However, false positives remain a concern, particularly when applying externally derived cutoffs that exhibited lower specificity which could have led to inappropriate treatment of A\u03b2-negative participants. Future research should focus on prospective validation of P-tau217 cutoffs to enhance their generalizability and inform standardized treatment decision-making across diverse populations.<\/p>","DOI":"10.21203\/rs.3.rs-3755419\/v1","type":"posted-content","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:02:59Z","timestamp":1716980579000},"source":"Crossref","is-referenced-by-count":2,"title":["Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer\u2019s disease"],"prefix":"10.21203","author":[{"given":"Matthew D.","family":"Howe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karysa J.","family":"Britton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Joyce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheina","family":"Emrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary J.","family":"Kunicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie A.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany C.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan C.","family":"Riddle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward D.","family":"Huey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shorena","family":"Janelidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen P.","family":"Salloway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials","volume":"3","author":"Hansson O","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319.","journal-title":"Nat Aging"},{"issue":"8","key":"ref2","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/s43587-022-00269-x","article-title":"Designing the next-generation clinical care pathway for Alzheimer\u2019s disease","volume":"2","author":"Hampel H","year":"2022","unstructured":"Hampel H, Au R, Mattke S, Van Der Flier WM, Aisen P, Apostolova L, et al. Designing the next-generation clinical care pathway for Alzheimer\u2019s disease. Nat Aging. 2022;2(8):692\u2013703.","journal-title":"Nat Aging"},{"issue":"2","key":"ref3","first-page":"221","article-title":"Aducanumab: Appropriate Use Recommendations Update","volume":"9","author":"Cummings J","year":"2022","unstructured":"Cummings J, Rabinovici GD, Atri A, Aisen P, Apostolova LG, Hendrix S, et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alz Dis. 2022;9(2):221\u201330.","journal-title":"J Prev Alz Dis"},{"key":"ref4","first-page":"1","article-title":"Lecanemab: Appropriate Use Recommendations","author":"Cummings J","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S et al. Lecanemab: Appropriate Use Recommendations. J Prev Alzheimer\u2019s Disease. 2023;1\u201316.","journal-title":"J Prev Alzheimer\u2019s Disease"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3233\/ADR230007","article-title":"Current Diagnostic Pathways for Alzheimer\u2019s Disease: A Cross-Sectional Real-World Study Across Six Countries","volume":"7","author":"Roth S","year":"2023","unstructured":"Roth S, Burnie N, Suridjan I, Yan JT, Carboni M. Current Diagnostic Pathways for Alzheimer\u2019s Disease: A Cross-Sectional Real-World Study Across Six Countries. J Alzheimers Dis Rep. 2023;7(1):659\u201374.","journal-title":"J Alzheimers Dis Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.trci.2019.11.008","article-title":"Racial disparities and temporal trends in dementia misdiagnosis risk in the United States","volume":"5","author":"Gianattasio KZ","year":"2019","unstructured":"Gianattasio KZ, Prather C, Glymour MM, Ciarleglio A, Power MC. Racial disparities and temporal trends in dementia misdiagnosis risk in the United States. Alzheimers Dement (N Y). 2019;5:891\u20138.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"e011146","DOI":"10.1136\/bmjopen-2016-011146","article-title":"Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis","volume":"7","author":"Lang L","year":"2017","unstructured":"Lang L, Clifford A, Wei L, Zhang D, Leung D, Augustine G, et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis. BMJ Open. 2017;7(2):e011146.","journal-title":"BMJ Open"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3233\/ADR-220023","article-title":"Under-Represented Populations Left Out of Alzheimer\u2019s Disease Treatment with Aducanumab: Commentary on Ethics","volume":"6","author":"Padala SP","year":"2022","unstructured":"Padala SP, Yarns BC. Under-Represented Populations Left Out of Alzheimer\u2019s Disease Treatment with Aducanumab: Commentary on Ethics. J Alzheimers Dis Rep. 2022;6(1):345\u20138.","journal-title":"J Alzheimers Dis Rep"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3233\/JAD-200133","article-title":"Pharmaceutical Treatment for Alzheimer\u2019s Disease and Related Dementias: Utilization and Disparities","volume":"76","author":"Barthold D","year":"2020","unstructured":"Barthold D, Joyce G, Ferido P, Drabo EF, Marcum ZA, Gray SL, et al. Pharmaceutical Treatment for Alzheimer\u2019s Disease and Related Dementias: Utilization and Disparities. J Alzheimers Dis. 2020;76(2):579\u201389.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton NJ","year":"2021","unstructured":"Ashton NJ, Leuzy A, Karikari TK, Mattsson-Carlgren N, Dodich A, Boccardi M, et al. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021;48(7):2140\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"ref11","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist S","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, et al. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA. 2020;324(8):772.","journal-title":"JAMA"},{"issue":"9","key":"ref12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","article-title":"Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease\u2013Related \u03b2-Amyloid Status","volume":"76","author":"Palmqvist S","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease\u2013Related \u03b2-Amyloid Status. JAMA Neurol. 2019;76(9):1060.","journal-title":"JAMA Neurol"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","article-title":"Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures","volume":"27","author":"Palmqvist S","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N, Zetterberg H, Blennow K, the Alzheimer\u2019s Disease Neuroimaging Initiative. Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034\u201342.","journal-title":"Nat Med"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","author":"Ashton NJ","year":"2024","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. 2024;81(3):255\u201363.","journal-title":"JAMA Neurol"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/alz.12706","article-title":"Test\u2010retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models","volume":"19","author":"Cullen NC","year":"2023","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, et al. Test\u2010retest variability of plasma biomarkers in Alzheimer\u2019s disease and its effects on clinical prediction models. Alzheimer\u2019s Dement. 2023;19(3):797\u2013806.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"9","key":"ref16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum WS","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390.","journal-title":"Nat Aging"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jamaneurol.2023.4596","article-title":"Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies","volume":"81","author":"Mattsson-Carlgren N","year":"2024","unstructured":"Mattsson-Carlgren N, Collij LE, Stomrud E, Pichet Binette A, Ossenkoppele R, Smith R, et al. Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol. 2024;81(1):69\u201378.","journal-title":"JAMA Neurol"},{"key":"ref18","author":"Lee A","year":"2017","unstructured":"Lee A, Alber J, Monast D, Menard W, Tang T, Bodge C et al. The Butler Alzheimer\u2019s Prevention Registry: Recruitment and Interim Outcome. In: Alzheimer\u2019s & Dementia. 2017. pp. 622\u20133."},{"issue":"4","key":"ref19","first-page":"765","article-title":"Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval","volume":"10","author":"Howe MD","year":"2023","unstructured":"Howe MD, Britton KJ, Joyce HE, Pappas GJ, Faust MA, Dawson BC, et al. Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated Approval. J Prev Alz Dis. 2023;10(4):765\u201370.","journal-title":"J Prev Alz Dis"},{"issue":"2","key":"ref20","first-page":"152","article-title":"The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer\u2019s Prevention Registry","volume":"10","author":"Lee AKW","year":"2023","unstructured":"Lee AKW, Collier MK, Thompson LI, Popescu D, Arthur E, Correia S, et al. The Effects of Subjective Cognitive Decline on APOE Genotype Disclosure in the Butler Hospital Alzheimer\u2019s Prevention Registry. J Prev Alz Dis. 2023;10(2):152\u201361.","journal-title":"J Prev Alz Dis"},{"issue":"4","key":"ref21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/brain\/awac333","article-title":"Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease","volume":"146","author":"Janelidze S","year":"2023","unstructured":"Janelidze S, Bali D, Ashton NJ, Barth\u00e9lemy NR, Vanbrabant J, Stoops E, et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer\u2019s disease. Brain. 2023;146(4):1592\u2013601.","journal-title":"Brain"},{"issue":"13","key":"ref22","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia","volume":"321","author":"Rabinovici GD","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286\u201394.","journal-title":"JAMA"},{"issue":"S9","key":"ref23","first-page":"S98","article-title":"Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer\u2019s Disease Study (LEADS)","volume":"19","author":"Cho H","year":"2023","unstructured":"Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, et al. Amyloid and tau-PET in early-onset AD: Baseline data from the Longitudinal Early-onset Alzheimer\u2019s Disease Study (LEADS). Alzheimer\u2019s Dement. 2023;19(S9):S98\u2013114.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3233\/JAD-180548","article-title":"Clinical Experience with Cerebrospinal Fluid A\u03b242, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia","volume":"65","author":"Tariciotti L","year":"2018","unstructured":"Tariciotti L, Casadei M, Honig LS, Teich AF, McKhann II GM, Tosto G, et al. Clinical Experience with Cerebrospinal Fluid A\u03b242, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. J Alzheimers Dis. 2018;65(4):1417\u201325.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","article-title":"CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts","volume":"14","author":"Hansson O","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, et al. CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimer\u2019s Dement. 2018;14(11):1470\u201381.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"8","key":"ref26","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1212\/WNL.52.8.1555","article-title":"Improved discrimination of AD patients using \u03b2-amyloid (1\u201342) and tau levels in CSF","volume":"52","author":"Hulstaert F","year":"1999","unstructured":"Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, Deyn PPD, et al. Improved discrimination of AD patients using \u03b2-amyloid (1\u201342) and tau levels in CSF. Neurology. 1999;52(8):1555\u20131555.","journal-title":"Neurology"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims JR","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial. JAMA. 2023;330(6):512.","journal-title":"JAMA"},{"key":"ref28","unstructured":"AAIC [Internet]. [cited 2023 Dec 4]. Revised Criteria for Diagnosis and Staging of Alzheimer\u2019s. \/\/aaic.alz.org\/diagnostic-criteria.asp."},{"issue":"8","key":"ref29","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease","volume":"29","author":"Horie K","year":"2023","unstructured":"Horie K, Salvad\u00f3 G, Barth\u00e9lemy NR, Janelidze S, Li Y, He Y, et al. CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med. 2023;29(8):1954\u201363.","journal-title":"Nat Med"},{"issue":"12","key":"ref30","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1002\/alz.12756","article-title":"The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease","volume":"18","author":"Hansson O","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, et al. The Alzheimer\u2019s Association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement. 2022;18(12):2669\u201386.","journal-title":"Alzheimers Dement"},{"key":"ref31","volume-title":"Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals","author":"Brum WS","unstructured":"Brum WS, Ashton NJ, Simr\u00e9n J, Di Molfetta G, Karikari TK, Benedet AL et al. Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimer\u2019s & Dementia. 2023;alz.13518."},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1038\/s41591-022-01822-2","article-title":"Performance of plasma phosphorylated tau 181 and 217 in the community","volume":"28","author":"Mielke MM","year":"2022","unstructured":"Mielke MM, Dage JL, Frank RD, Algeciras-Schimnich A, Knopman DS, Lowe VJ, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat Med. 2022;28(7):1398\u2013405.","journal-title":"Nat Med"},{"issue":"10","key":"ref33","doi-asserted-by":"crossref","first-page":"e2235068","DOI":"10.1001\/jamanetworkopen.2022.35068","article-title":"Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors","volume":"5","author":"Hajjar I","year":"2022","unstructured":"Hajjar I, Yang Z, Okafor M, Liu C, Waligorska T, Goldstein FC, et al. Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors. JAMA Netw Open. 2022;5(10):e2235068.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.3233\/JAD-201318","article-title":"Why Inclusion Matters for Alzheimer\u2019s Disease Biomarker Discovery in Plasma","volume":"79","author":"Khan MJ","year":"2021","unstructured":"Khan MJ, Desaire H, Lopez OL, Kamboh MI, Robinson RAS. Why Inclusion Matters for Alzheimer\u2019s Disease Biomarker Discovery in Plasma. J Alzheimers Dis. 2021;79(3):1327\u201344.","journal-title":"J Alzheimers Dis"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1001\/jamaneurol.2022.3157","article-title":"Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia\u2013Evidence for Amyloid Scanning (IDEAS) Cohort Study","volume":"79","author":"Wilkins CH","year":"2022","unstructured":"Wilkins CH, Windon CC, Dilworth-Anderson P, Romanoff J, Gatsonis C, Hanna L, et al. Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia: A Secondary Analysis of the Imaging Dementia\u2013Evidence for Amyloid Scanning (IDEAS) Cohort Study. JAMA Neurol. 2022;79(11):1139\u201347.","journal-title":"JAMA Neurol"},{"key":"ref36","article-title":"Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer\u2019s disease: racial differences","author":"Xu C","year":"2023","unstructured":"Xu C, Xiao D, Su BB, Saveron JM, Gamez D, Navia RO et al. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer\u2019s disease: racial differences. Neurol Sci. 2023;[ePub ahead of print].","journal-title":"Neurol Sci"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3755419\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3755419\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T11:03:24Z","timestamp":1716980604000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3755419\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,29]]},"references-count":36,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3755419\/v1","relation":{},"subject":[],"published":{"date-parts":[[2024,5,29]]},"subtype":"preprint"}}